This article looks at what a transition to propellants with lower Global Warming Potential will involve and the lessons that can be learned from the industry’s earlier transition from CFCs to HFAs. Key issues that need to be addressed as formulators learn to work with propellants such as HFA 152a and HFO 1234ze include solubility of the active, the profile of the emitted spray, droplet size and evaporation, and electrostatic characteristics.
Aptar Pharma offers a comprehensive suite of services for those looking to accelerate their transition to low carbon MDIs including the Nanopharm SmartTrack™ platform which provides a wealth of information for formulation optimization.
Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery
This Might Also Be of Interest
Investigating Breathable HPV-L2 Dry Powder Vaccine using GLA as Amphiphilic Lubricant...
Publications, Pharmaceutical, Innovation & Insights, Drug Delivery Innovations, Product Solutions
Using digital devices to boost patient outcomes in respiratory health
Webinars, Pharmaceutical, Market Insights, Product Solutions, Drug Delivery Innovations
The Industry Speaks as One: Towards a More Sustainable Future with pMDI Solutions
Publications, Pharmaceutical, Sustainability, Innovation & Insights, Drug Delivery Innovations, Product Solutions
Successfully Balancing The Needs of The Planet With The Needs of The Patient
Publications, Pharmaceutical, Sustainability, Innovation & Insights, Drug Delivery Innovations, Product Solutions
